Skip to main content

Table 1 IC50 of pan-HER inhibitors applied before stimulation with HER agonists from six primary breast cancer cell samples with hyperactive HER- and c-Met signaling

From: Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

Pan-HER inhibitors

Average IC50 (nM)

Poziotinib*

1.23

Neratinib

4.81

Ibrutinib

13.10

Dacomitinib

22.06

Sapitinib

41.28

Lapatinib

137.27

Tucatinib#

333

  1. *Poziotinib average IC50 was derived from dose response on three primary breast cancer cell samples
  2. #Tucatinib (HER2 specific) average IC50 was derived from dose response on five primary breast cancer cell samples
Back to article page

Cell Communication and Signaling

ISSN: 1478-811X